What is the optimal age for starting lipid lowering treatment? A mathematical model.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial.BMC medical informatics and decision making · 2016
   Trial
2. The Optimizing-Risk-Communication (OptRisk) randomized trial - impact of decision-aid-based consultation on adherence and perception of cardiovascular risk.Patient preference and adherence · 2019
   Article
3. The effect of a new lifetime-cardiovascular-risk display on patients' motivation to participate in shared decision-making.BMC family practice · 2018
   Article
4. Challenges in the pharmacologic management of obesity and secondary dyslipidemia in children and adolescents.Paediatric drugs · 2013
   Review
5. Treatment of dyslipidemia in the elderly.Journal of geriatric cardiology : JGC · 2011
   Article
6. Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom.British journal of clinical pharmacology · 2008
   Article
7. Prevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.BMC public health · 2006
   Article
8. Treatment of high blood pressure and gain in event-free life expectancy.Vascular health and risk management · 2005
   Article
9. New and emerging data from clinical trials of statins.Current atherosclerosis reports · 2004
   Review
10. Cardiovascular and coronary risk estimation in hypertension management.Heart (British Cardiac Society) · 2002
    Review
11. Should pediatric patients with hyperlipidemia receive drug therapy?Paediatric drugs · 2002
    Review
12. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.BMJ (Clinical research ed.) · 2001
    Review
13. The current status of primary prevention in coronary heart disease.Current controlled trials in cardiovascular medicine · 2001
    Article
14. Statins: underused by those who would benefit.BMJ (Clinical research ed.) · 2000
    Article
15. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.BMJ (Clinical research ed.) · 2000
    Article

Corrections and comments

• Commented on by
  Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.2000
• Commented on by
  Optimal age for starting lipid lowering treatment. It is more efficient to screen and treat elderly people.2000
• Commented on by
  Optimal age for starting lipid lowering treatment. Adjusted date do not justify a lower optimal age.2000
• Erratum issued

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as